Behavioral economic analysis of topiramate pharmacotherapy for alcohol: a placebo-controlled investigation of effects on alcohol reinforcing value and delayed reward discounting.
Alcohol expenditure
Alcohol purchase task
Behavioral economics
Delayed reward discounting
Topiramate
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
02
07
2021
accepted:
22
11
2021
pubmed:
5
1
2022
medline:
22
1
2022
entrez:
4
1
2022
Statut:
ppublish
Résumé
Pharmacotherapies are an important clinical strategy for treating alcohol use disorder and an understanding of their functional mechanisms can inform optimal use. Behavioral economics provides a translational platform that may advance our understanding of the motivational impacts of pharmacotherapies. This secondary analysis study examined the effect of topiramate, a promising pharmacotherapy for treating alcohol use disorder, on two behavioral economic domains, the reinforcing value of alcohol (alcohol demand and alcohol-specific monetary expenditures) and delayed reward discounting (preference for smaller immediate rewards over larger delayed rewards). A double-blind randomized placebo-controlled study (n = 99) was conducted with non-treatment seeking heavy drinkers, comparing topiramate (target dose of 200 mg/day titrated for 3 weeks and remained at the target dose for 2 weeks) to matched placebo. We found that compared to placebo, topiramate reduced the reinforcing value of alcohol, as shown by a reduction in two alcohol demand indices (intensity and O This study provides evidence that topiramate reduces alcohol's reinforcing value as measured by alcohol demand and alcohol expenditure. More broadly, these findings support the utility of behavioral economics for understanding how medications reduce alcohol use.
Identifiants
pubmed: 34981180
doi: 10.1007/s00213-021-06034-z
pii: 10.1007/s00213-021-06034-z
pmc: PMC8776590
mid: NIHMS1768877
doi:
Substances chimiques
Topiramate
0H73WJJ391
Ethanol
3K9958V90M
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-161Subventions
Organisme : NIAAA NIH HHS
ID : K01 AA026874
Pays : United States
Organisme : NIAAA NIH HHS
ID : K23 AA016936
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA026326
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA007850
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Amlung M, MacKillop J (2011) Delayed reward discounting and alcohol misuse: the roles of response consistency and reward magnitude. J Exp Psychopathol 2(3):418–431. https://doi.org/10.5127/jep.017311
doi: 10.5127/jep.017311
pubmed: 25191534
pmcid: 4151982
Amlung M, MacKillop J (2015) Further evidence of close correspondence for alcohol demand decision making for hypothetical and incentivized rewards. Behav Processes 113:187–191. https://doi.org/10.1016/j.beproc.2015.02.012
doi: 10.1016/j.beproc.2015.02.012
pubmed: 25712039
pmcid: 4362679
Amlung M, Acker J, Stojek MK, Murphy JG, MacKillop J (2012) Is talk “cheap”? An initial investigation of the equivalence of alcohol purchase task performance for hypothetical and actual rewards. Alcohol Clin Exp Res 36(4):716–724. https://doi.org/10.1111/j.1530-0277.2011.01656.x
doi: 10.1111/j.1530-0277.2011.01656.x
pubmed: 22017303
Amlung M, Vedelago L, Acker J, Balodis I, MacKillop J (2017) Steep delay discounting and addictive behavior: a meta-analysis of continuous associations. Addiction 112(1):51–62. https://doi.org/10.1111/add.13535
doi: 10.1111/add.13535
pubmed: 27450931
Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, . . . Cogliano V (2007) Carcinogenicity of alcoholic beverages. Lancet Oncol 8(4): 292-293. https://doi.org/10.1016/s1470-2045(07)70099-2
Baker F, Johnson MW, Bickel WK (2003) Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude. J Abnorm Psychol 112(3):382–392. https://doi.org/10.1037/0021-843x.112.3.382
doi: 10.1037/0021-843x.112.3.382
pubmed: 12943017
Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103(12):2035–2044. https://doi.org/10.1111/j.1360-0443.2008.02355.x
doi: 10.1111/j.1360-0443.2008.02355.x
pubmed: 18855810
Banks ML, Negus SS (2017) Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci 38(2):181–194. https://doi.org/10.1016/j.tips.2016.11.002
doi: 10.1016/j.tips.2016.11.002
pubmed: 27916279
Bickel WK, Marsch LA (2001) Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction 96(1):73–86. https://doi.org/10.1046/j.1360-0443.2001.961736.x
doi: 10.1046/j.1360-0443.2001.961736.x
pubmed: 11177521
Blodgett JC, Del Re AC, Maisel NC, Finney JW (2014) A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38(6):1481–1488. https://doi.org/10.1111/acer.12411
doi: 10.1111/acer.12411
pubmed: 24796492
pmcid: 4047180
Breslin FJ, Johnson BA, Lynch WJ (2010) Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology 207(4):529–534
doi: 10.1007/s00213-009-1683-4
Brown SO, Effinger DP, Montoro RA, Daddaoua N, Justinova Z Moerke MJ, . . . Bradberry CW (2021) Economic choice between remifentanil and food in squirrel monkeys. Neuropsychopharmacology. https://doi.org/10.1038/s41386-021-00996-6
Bujarski S, MacKillop J, Ray LA (2012) Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. Exp Clin Psychopharmacol 20(3):181–190. https://doi.org/10.1037/a0027379
doi: 10.1037/a0027379
pubmed: 22429255
pmcid: 3741097
Del Re AC, Maisel N, Blodgett J, Finney J (2013) The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis. Alcohol Clin Exp Res 37(6):1064–1068. https://doi.org/10.1111/acer.12067
doi: 10.1111/acer.12067
pubmed: 23398164
pmcid: 3657572
Gray JC, Amlung MT, Palmer AA, MacKillop J (2016) Syntax for calculation of discounting indices from the monetary choice questionnaire and probability discounting questionnaire. J Exp Anal Behav 106(2):156–163. https://doi.org/10.1002/jeab.221
doi: 10.1002/jeab.221
pubmed: 27644448
Green R, Ray LA (2018) Effects of varenicline on subjective craving and relative reinforcing value of cigarettes. Drug Alcohol Depend 188:53–59
doi: 10.1016/j.drugalcdep.2018.03.037
Hogarth L, Field M (2020) Relative expected value of drugs versus competing rewards underpins vulnerability to and recovery from addiction. Behav Brain Res 394:112815. https://doi.org/10.1016/j.bbr.2020.112815
doi: 10.1016/j.bbr.2020.112815
pubmed: 32707138
pmcid: 7495042
Hursh SR, Galuska CM, Winger G, Woods JH (2005) The economics of drug abuse: a quantitative assessment of drug demand. Mol Interv 5(1):20–28. https://doi.org/10.1124/mi.5.1.6
doi: 10.1124/mi.5.1.6
pubmed: 15731502
Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, Liu L (2013) Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiat 70(12):1338–1346. https://doi.org/10.1001/jamapsychiatry.2013.2295
doi: 10.1001/jamapsychiatry.2013.2295
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, . . . Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361(9370): 1677-1685. https://doi.org/10.1016/s0140-6736(03)13370-3
Kenna GA (2005) Pharmacotherapy of alcohol dependence: targeting a complex disorder. Drug Discov Today Ther Strateg 2(1):71–78. https://doi.org/10.1016/j.ddstr.2005.04.001
doi: 10.1016/j.ddstr.2005.04.001
Kirby KN, Petry NM, Bickel WK (1999) Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 128(1):78–87. https://doi.org/10.1037//0096-3445.128.1.78
doi: 10.1037//0096-3445.128.1.78
pubmed: 10100392
Koffarnus MN, Franck CT, Stein JS, Bickel WK (2015) A modified exponential behavioral economic demand model to better describe consumption data. Exp Clin Psychopharmacol 23(6):504–512. https://doi.org/10.1037/pha0000045
doi: 10.1037/pha0000045
pubmed: 26280591
pmcid: 4854291
Kranzler HR, Soyka M (2018) Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 320(8):815–824. https://doi.org/10.1001/jama.2018.11406
doi: 10.1001/jama.2018.11406
pubmed: 30167705
pmcid: 7391072
Lagorio CH, Madden GJ (2005) Delay discounting of real and hypothetical rewards III: steady-state assessments, forced-choice trials, and all real rewards. Behav Processes 69(2):173–187. https://doi.org/10.1016/j.beproc.2005.02.003
doi: 10.1016/j.beproc.2005.02.003
pubmed: 15845306
Libarino-Santos M, Brandão NR, Borges ÁL, Anjos-Santos A, Cata-Preta EG, Barros-Santos T, . . . Kisaki ND (2021) Aripiprazole and topiramate, alone or in combination, block the expression of ethanol-induced conditioned place preference in mice. Drug Alcohol Depend 220: 108520
MacKillop J (2016) The behavioral economics and neuroeconomics of alcohol use disorders. Alcohol Clin Exp Res 40(4):672–685. https://doi.org/10.1111/acer.13004
doi: 10.1111/acer.13004
pubmed: 26993151
pmcid: 4846981
MacKillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munafò MR (2011) Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology 216(3):305–321. https://doi.org/10.1007/s00213-011-2229-0
doi: 10.1007/s00213-011-2229-0
pubmed: 21373791
pmcid: 3201846
MacKillop J, Miranda R Jr, Monti PM, Ray LA, Murphy JG, Rohsenow DJ, . . . Gwaltney CJ (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. J Abnorm Psychol 119(1): 106-114. https://doi.org/10.1037/a0017513
Madden GJ, Bickel WK, Jacobs EA (1999) Discounting of delayed rewards in opioid-dependent outpatients: exponential or hyperbolic discounting functions? Exp Clin Psychopharmacol 7(3):284–293. https://doi.org/10.1037/1064-1297.7.3.284
doi: 10.1037/1064-1297.7.3.284
pubmed: 10472517
Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108(2):275–293. https://doi.org/10.1111/j.1360-0443.2012.04054.x
doi: 10.1111/j.1360-0443.2012.04054.x
pubmed: 23075288
Maxwell SE, Cole DA (2007) Bias in cross-sectional analyses of longitudinal mediation. Psychol Methods 12(1):23
doi: 10.1037/1082-989X.12.1.23
McClure EA, Vandrey RG, Johnson MW, Stitzer ML (2012) Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob Res 15(1):139–148
doi: 10.1093/ntr/nts101
Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, . . . McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32(3): 489-497. https://doi.org/10.1111/j.1530-0277.2007.00592.x
Miranda R Jr, MacKillop J, Treloar H, Blanchard A, Tidey JW, Swift RM, . . . Monti PM (2016) Biobehavioral mechanisms of topiramate’s effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. Addict Biol 21(1): 171-182. https://doi.org/10.1111/adb.12192
Murphy JG, MacKillop J (2006) Relative reinforcing efficacy of alcohol among college student drinkers. Exp Clin Psychopharmacol 14(2):219–227. https://doi.org/10.1037/1064-1297.14.2.219
doi: 10.1037/1064-1297.14.2.219
pubmed: 16756426
Murphy JG, MacKillop J, Skidmore JR, Pederson AA (2009) Reliability and validity of a demand curve measure of alcohol reinforcement. Exp Clin Psychopharmacol 17(6):396–404. https://doi.org/10.1037/a0017684
doi: 10.1037/a0017684
pubmed: 19968404
O’Laughlin KD, Martin MJ, Ferrer E (2018) Cross-sectional analysis of longitudinal mediation processes. Multivar Behav Res 53(3):375–402
doi: 10.1080/00273171.2018.1454822
Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR (2014) Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res 16(3):288–296. https://doi.org/10.1093/ntr/ntt141
doi: 10.1093/ntr/ntt141
pubmed: 24057996
Rubio G, Martínez-Gras I, Manzanares J (2009) Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 29(6):584–589. https://doi.org/10.1097/JCP.0b013e3181bfdb79
doi: 10.1097/JCP.0b013e3181bfdb79
pubmed: 19910725
SAMHSA (2020a) Results from the 2019 National Survey on Drug Use and Health. Table 2.21B. Retrieved from https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetTabsSect2pe2019.htm ?s=2.21&#tab2-21b. Accessed March 2021
SAMHSA (2020b) Results from the 2019 National Survey on Drug Use and Health. Table 5.18B. Retrieved from https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetTabsSect5pe2019.htm ?s=5.18&#tab5-18b. Accessed March 2021
Smith AP, Beckmann JS (2021) Quantifying value-based determinants of drug and non-drug decision dynamics. Psychopharmacology 238(8):2047–2057. https://doi.org/10.1007/s00213-021-05830-x
doi: 10.1007/s00213-021-05830-x
pubmed: 33839902
pmcid: 8529627
Sobell LC, Sobell MB (1992) Timeline follow-back. In Measuring alcohol consumption. Springer, pp 41–72
Strickland JC, Lacy RT (2020) Behavioral economic demand as a unifying language for addiction science: promoting collaboration and integration of animal and human models. Exp Clin Psychopharmacol 28(4):404–416. https://doi.org/10.1037/pha0000358
doi: 10.1037/pha0000358
pubmed: 32105136
pmcid: 7390687